10-Q: GRI Bio Faces Going Concern Doubt Amid Rising Losses
Quarterly Report
GRI Bio reported increased net losses and a declining cash position, raising substantial doubt about its ability to continue as a going concern, despite progress in clinical trials and recent capital raises.
Summary
- Net loss for the three months ended September 30, 2025, increased to $3.359 million, up from $2.123 million in the prior year period.
- Net loss for the nine months ended September 30, 2025, increased to $9.297 million, up from $6.259 million in the prior year period.
- Cash and cash equivalents decreased to $4.055 million as of September 30, 2025, from $5.028 million at December 31, 2024.
- Accumulated deficit grew to $49.037 million as of September 30, 2025.
- Research and development expenses increased by $0.7 million for the three months and $2.3 million for the nine months ended September 30, 2025, primarily due to the GRI-0621 development program.
- General and administrative expenses increased by $0.6 million for the three months and $0.7 million for the nine months ended September 30, 2025, mainly due to personnel and public company expenses.
- The company completed enrollment for its Phase 2a biomarker study of GRI-0621 in July 2025, with topline results expected by the end of November 2025.
- Successfully raised $4.0 million in net proceeds from an April 2025 public offering and $2.5 million in net proceeds from an At-The-Market (ATM) offering during the nine months ended September 30, 2025.
- Management identified a material weakness in internal control over financial reporting related to the inaccurate computation of a non-cash deemed dividend associated with a warrant repricing.
Sentiment
Score: 3
Explanation: While clinical progress for GRI-0621 is noted, the significant increase in net losses, declining cash position, and explicit 'going concern' warning indicate a highly negative financial situation. The successful capital raises are necessary but not sufficient to alleviate the fundamental financial challenges, leading to a low sentiment score.
Positives
- Enrollment for the Phase 2a biomarker study of GRI-0621 was completed in July 2025, with topline results anticipated by the end of November 2025.
- Preliminary data from GRI-0621 trials indicate the drug is well-tolerated and shows biomarker changes suggestive of an anti-fibrotic effect.
- The U.S. FDA has cleared the Investigative New Drug (IND) application for GRI-0621, and clinical trial authorization has been received from the UK and Australia.
- Successfully raised $4.0 million in net proceeds from the April 2025 Public Offering and $2.5 million in net proceeds from the At-The-Market (ATM) offering during the nine months ended September 30, 2025.
Negatives
- Net loss for the three months ended September 30, 2025, increased to $3.359 million from $2.123 million in the prior year period.
- Net loss for the nine months ended September 30, 2025, increased to $9.297 million from $6.259 million in the prior year period.
- Cash and cash equivalents decreased to $4.055 million as of September 30, 2025, from $5.028 million at December 31, 2024.
- The accumulated deficit reached $49.037 million as of September 30, 2025.
- Operating expenses significantly increased, with research and development up $0.7 million (three months) and $2.3 million (nine months), and general and administrative up $0.6 million (three months) and $0.7 million (nine months).
- There is substantial doubt about the company's ability to continue as a going concern for a period of one year from the issuance of these financial statements.
- Development of the product candidate GRI-0803 is limited pending additional funding.
- A material weakness in internal control over financial reporting was identified related to the inaccurate computation of a non-cash deemed dividend.
Risks
- Substantial doubt exists about the company's ability to continue as a going concern due to continued operating losses and the need for significant additional funding.
- The company may be unable to raise additional capital on acceptable terms or at all, which could force reductions in spending, delays or elimination of development programs, or cessation of operations.
- The success of the company is highly dependent on the successful development, regulatory approval, and commercialization of its product candidates, GRI-0621 and GRI-0803, which are in early stages of development.
- Competition from existing approved therapies for Idiopathic Pulmonary Fibrosis (IPF) and other target diseases poses a risk to future market penetration.
- A material weakness in internal control over financial reporting was identified, which could adversely affect the company's ability to record, process, summarize, and report financial information accurately.
Future Outlook
GRI Bio expects to release topline results from its Phase 2a biomarker study for GRI-0621 by the end of November 2025. The company intends to complete IND-enabling studies and file an IND application for GRI-0803 for a Phase 1a and 1b trial in 2026, contingent on securing additional funding and IND clearance. The company anticipates continued operating losses and increasing research and development expenses as it advances its product candidates. Existing cash and cash equivalents are projected to fund operations only into the first quarter of 2026, necessitating substantial additional capital raises.
Management Comments
- Our goal is to be an industry leader in developing therapies to treat these diseases and to improve the lives of patients suffering from such diseases.
- In preliminary data from our trials to date with GRI-0621, and earlier trials with oral tazarotene, we have observed GRI-0621 to be well-tolerated and to inhibit iNKT cell activity in subjects.
- Changes from baseline of biomarkers in GRI-0621 treated subjects were suggestive of an anti-fibrotic effect, with decreases in biomarkers of fibrosis formation and increases in biomarkers of fibrosis resolution observed.
- In order to focus our resources on our GRI-0621 program, we have limited our development of GRI-0803 pending additional funding.
- We expect our research and development expenses to increase over the next several years as we conduct our planned clinical and preclinical activities for our product candidates.
- Based on our current operating plan, we believe that our existing cash and cash equivalents will be sufficient to fund our operating expenses and capital expenditure requirements into the first quarter of 2026.
- Accordingly, we will need to obtain substantial additional funding in connection with our continuing operations.
- There is substantial doubt about our ability to continue as a going concern.
Industry Context
GRI Bio operates in the highly competitive clinical-stage biopharmaceutical sector, focusing on developing novel therapies for inflammatory, fibrotic, and autoimmune disorders. Its lead candidate, GRI-0621, targets Idiopathic Pulmonary Fibrosis (IPF), a severe lung disease with significant unmet medical needs, as current approved therapies often have substantial side effects and do not improve overall survival. The company's other candidate, GRI-0803, aims to address autoimmune conditions like Systemic Lupus Erythematosus (SLE) and Multiple Sclerosis (MS), areas also characterized by limited treatment options and high patient burden. The company's approach of targeting Natural Killer T (iNKT) cells represents a specific immunological strategy within these therapeutic landscapes.
Comparison to Industry Standards
- The company highlights that existing approved therapies for Idiopathic Pulmonary Fibrosis (IPF) have not been associated with improvements in overall survival and are linked to significant side effects, suggesting GRI-0621 aims to offer a superior profile.
- For Systemic Lupus Erythematosus (SLE), the company notes that only two drugs have been approved in the past 50 years, indicating a substantial unmet need compared to other therapeutic areas with more active drug development.
Management Changes
| Role | Previous Person | New Person | Effective Date | Reason |
|---|---|---|---|---|
| Former Chief Executive Officer | David Baker | NA | 2023-04-21 | Resignation, followed by a Separation and Release Agreement. |
Corporate Governance
| Change Type | Description | Effective Date | Impact Assessment |
|---|---|---|---|
| Equity Incentive Plan Amendment | Stockholders approved an amendment to the Amended and Restated 2018 Equity Incentive Plan to increase the aggregate number of shares by 400,000. | 2025-08-13 | Increases the pool of shares available for equity-based awards to employees, directors, and consultants, potentially impacting future dilution. |
| Internal Control Weakness | Management identified a material weakness related to the inaccurate computation of a non-cash deemed dividend associated with the repricing of Series B Common Warrants. | NA | Indicates a deficiency in financial reporting controls, potentially affecting the reliability of financial statements. Management has implemented a remediation plan. |
Legal Proceedings
- The company is not currently a party to any material legal proceedings and is not aware of any pending or threatened legal proceeding that could have an adverse effect on its business, operating results, or financial condition.
Stakeholder Impact
- Shareholders face significant dilution risk from past and future equity offerings necessary to fund operations, alongside potential volatility due to the company's financial condition and upcoming clinical trial results.
- Employees' job security and compensation, particularly stock-based awards, are dependent on the company's ability to secure additional funding and continue operations.
- Creditors face increased risk due to the company's growing losses, declining cash position, and the explicit 'going concern' warning.
- Patients suffering from Idiopathic Pulmonary Fibrosis (IPF) and autoimmune disorders like Systemic Lupus Erythematosus (SLE) and Multiple Sclerosis (MS) could potentially benefit from new therapeutic options if GRI-0621 and GRI-0803 successfully advance through clinical development.
Next Steps
- Release topline results from the Phase 2a biomarker study for GRI-0621 by the end of November 2025.
- Complete IND-enabling studies and file an IND application to evaluate GRI-0803 in a Phase 1a and 1b trial in 2026, subject to additional funding and IND clearance.
- Obtain substantial additional funding through equity or debt arrangements to continue operations beyond the first quarter of 2026.
- Continue to implement a plan to remediate the material weakness in internal control over financial reporting.
Key Dates
| Date | Description |
|---|---|
| 2023-04-21 | Stockholders approved the Amended and Restated 2018 Equity Incentive Plan. Separation and Release Agreement entered with former CEO David Baker. |
| 2023-12-01 | Enrollment commenced for the Phase 2a biomarker study evaluating GRI-0621 for the treatment of IPF. |
| 2024-01-29 | Effected a one-for-seven reverse stock split of common stock. |
| 2024-02-01 | Entered into the February 2024 Purchase Agreement for a public offering, generating net proceeds of $4.389 million. |
| 2024-02-06 | Issuance date for Series B-1 and B-2 Common Warrants. |
| 2024-03-14 | Filed Annual Report on Form 10-K for the year ended December 31, 2024. |
| 2024-05-20 | Entered into an At The Market Offering Agreement with H.C. Wainwright & Co., LLC to sell up to $10.0 million of common stock. |
| 2024-06-17 | Effected a one-for-thirteen reverse stock split of common stock. |
| 2024-06-26 | Entered into the June 2024 Purchase Agreement for a public offering, generating net proceeds of $3.172 million. |
| 2024-09-06 | Beginning date for the five-year exercise period for Series C-1 Common Warrants and 18-month exercise period for Series C-2 Common Warrants. |
| 2024-10-21 | Entered into Repricing Letter Agreements with certain warrant holders, resulting in net proceeds of $609,000 from warrant exercises. |
| 2024-10-22 | Expiration date for Series D-1 Common Warrants and October 2024 PA Warrants. |
| 2025-01-02 | Expiration date for Series E-3 Common Warrants. |
| 2025-02-21 | Effected a one-for-seventeen reverse stock split of common stock. |
| 2025-04-01 | Entered into the April 2025 Purchase Agreement for a public offering, generating net proceeds of $4.020 million. Expiration date for April 2025 PA Warrants. |
| 2025-04-02 | April 2025 Offering closed. Expiration date for Series E-1 Common Warrants. |
| 2025-04-22 | Expiration date for Series D-2 Common Warrants. |
| 2025-05-23 | Filed a prospectus supplement to increase the At-The-Market (ATM) offering capacity by up to $1.8 million. |
| 2025-07-01 | Enrollment completed for the Phase 2a biomarker study of GRI-0621. |
| 2025-08-13 | Stockholders approved an amendment to the Amended and Restated 2018 Equity Incentive Plan to increase shares by 400,000. |
| 2025-09-30 | End of the current quarterly reporting period. |
| 2025-10-02 | Expiration date for Series E-2 Common Warrants. |
| 2025-11-13 | Date as of which 3,268,727 shares of common stock were outstanding. |
| 2025-11-14 | Date of filing of the Quarterly Report on Form 10-Q. |
| 2025-11-30 | Expected release of topline results from the Phase 2a biomarker study for GRI-0621. |
| 2026-01-01 | Expected period when existing cash and cash equivalents will be sufficient to fund operating expenses and capital expenditure requirements into. |
Recommendation
sellThe company faces significant financial distress, evidenced by increasing net losses, declining cash, and an explicit 'going concern' warning. While there is ongoing clinical development for GRI-0621, the company's ability to fund operations beyond Q1 2026 is uncertain, necessitating substantial additional capital raises which will likely lead to further dilution. The material weakness in internal controls also adds to operational risk. Given the high burn rate and precarious financial position, the stock carries substantial risk for investors.
Keywords
Biopharmaceutical, Clinical-stage, Idiopathic Pulmonary Fibrosis, IPF, GRI-0621, Autoimmune disorders, Systemic Lupus Erythematosus, Lupus, Multiple Sclerosis, MS, GRI-0803, iNKT cells, SEC filing, 10-Q, Biotechnology, Drug development, Going concern, Capital raise, Warrants, Clinical trials
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.